A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.
Multiple Myeloma
BIOLOGICAL: CTX120
Part A (dose escalation): Incidence of adverse events, Adverse events defined as dose-limiting toxicities, From CTX120 infusion up to 28 days post-infusion|Part B (cohort expansion): Objective response rate, Objective response rate per International Myeloma Working Group (IMWG) response criteria., From CTX120 infusion up to 60 months post-infusion
Progression Free Survival, From date of CTX120 infusion and date of disease progression or death due to any cause, assessed up to 60 months|Overall Survival, From date of CTX120 infusion until date of death due to any cause, assessed up to 60 months
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.